佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月26日南向资金增持35.7万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金增 持的有4天，累计净增持278.46万股。近20个交易日中，获南向资金增持的有11天，累计净增持720.84万 股。截至目前，南向资金持有佰泽医疗（02609.HK）7570.44万股，占公司已发行普通股的5.73%。 ...

佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月23日南向资金增持196.32万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金 增持的有3天，累计净增持87.0万股。近20个交易日中，获南向资金增持的有11天，累计净增持727.56万 股。截至目前，南向资金持有佰泽医疗（02609.HK）7534.74万股，占公司已发行普通股的5.71%。 ...

Core Viewpoint - The Hong Kong stock market is facing a significant wave of lock-up share releases in February and March 2026, with many companies experiencing high percentages of shares being unlocked, potentially impacting stock prices and market sentiment [2][4]. Group 1: Companies Facing High Unlock Ratios - Several companies, including Mirxes-B, Nanshan Aluminium International, and Jiangsu Hongxin, have over 50% of their total share capital subject to unlock, indicating substantial potential selling pressure [2][3]. - The first tier of companies with high unlock ratios includes Different Group (84.67%), Nanshan Aluminium International (80.59%), and Jiangsu Hongxin (68.19%) [3]. Group 2: Market Impact and Investor Behavior - The upcoming unlocks may lead to market panic selling, particularly for small-cap stocks and loss-making companies, as investors may preemptively sell to mitigate risk [9]. - Companies with lock-up commitments, such as Mirxes-B, may experience reduced selling pressure due to commitments from founders and cornerstone investors to hold their shares for an extended period [5][9]. Group 3: Long-term Implications of Unlocks - The unlocking of shares may lead to a more diversified shareholder structure, reducing the risk of concentrated ownership and enhancing corporate governance transparency [10]. - Ultimately, the long-term impact on stock prices will depend on the companies' fundamentals, growth prospects, and industry conditions, rather than solely on the unlock events [10][11].

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 证券之星消息，2月13日南向资金增持164.94万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金 增持的有2天，累计净增持46.74万股。近20个交易日中，获南向资金增持的有11天，累计净增持801.6万 股。截至目前，南向资金持有佰泽医疗（02609.HK）7309.44万股，占公司已发行普通股的5.54%。 ...

佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月12日南向资金减持147.48万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金 减持的有4天，累计净减持154.56万股。近20个交易日中，获南向资金增持的有10天，累计净增持537.42 万股。截至目前，南向资金持有佰泽医疗（02609.HK）7144.5万股，占公司已发行普通股的5.41%。 ...

Core Insights - Tencent Holdings (00700), Southern Hang Seng Technology (03033), and Xiaomi Group-W (01810) ranked as the top three in net inflow of southbound funds, with net inflows of 1.792 billion, 0.571 billion, and 0.412 billion respectively [1] - The top three in net outflow of southbound funds were Yingfu Fund (02800), Hang Seng China Enterprises (02828), and Kuaishou-W (01024), with net outflows of -4.553 billion, -1.380 billion, and -0.576 billion respectively [1] - In terms of net inflow ratio, Huaxia Hang Seng Technology (03088), Southern East Selection (03441), and Anhui Wantuo Expressway (00995) led the market with ratios of 90.53%, 74.02%, and 68.27% respectively [1] - The top three in net outflow ratio were Southern Hong Kong Stock Connect (03432), Fuyao Glass (06865), and Baize Medical (02609) with ratios of -100.00%, -59.27%, and -53.09% respectively [1] Net Inflow Rankings - Tencent Holdings (00700) had a net inflow of 1.792 billion, representing a 12.21% increase, closing at 560.000 (+2.28%) [2] - Southern Hang Seng Technology (03033) saw a net inflow of 0.571 billion, with a 6.77% increase, closing at 5.300 (+1.34%) [2] - Xiaomi Group-W (01810) recorded a net inflow of 0.412 billion, with a 9.45% increase, closing at 35.200 (+0.06%) [2] Net Outflow Rankings - Yingfu Fund (02800) experienced the highest net outflow of -4.553 billion, with a -22.13% decrease, closing at 27.220 (+1.72%) [2] - Hang Seng China Enterprises (02828) had a net outflow of -1.380 billion, representing an -11.37% decrease, closing at 93.940 (+1.56%) [2] - Kuaishou-W (01024) faced a net outflow of -0.576 billion, with a -10.25% decrease, closing at 69.300 (-2.74%) [2] Net Inflow Ratio Rankings - Huaxia Hang Seng Technology (03088) led with a net inflow ratio of 90.53%, with a net inflow of 47.6883 million, closing at 6.875 (+1.33%) [3] - Southern East Selection (03441) followed with a net inflow ratio of 74.02%, with a net inflow of 18.0421 million, closing at 11.600 (+1.13%) [3] - Anhui Wantuo Expressway (00995) had a net inflow ratio of 68.27%, with a net inflow of 5.6553 million, closing at 13.340 (-0.07%) [3]

证券之星消息，2月11日南向资金减持155.76万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金 减持的有4天，累计净减持77.58万股。近20个交易日中，获南向资金增持的有11天，累计净增持690.0万 股。截至目前，南向资金持有佰泽医疗（02609.HK）7291.98万股，占公司已发行普通股的5.52%。 佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Insights - The core viewpoint of the articles is that Baize Medical is innovating the healthcare model through its Hospital at Home (H@H) approach, which integrates value-based and digital healthcare, transforming traditional hospital operations into a technology-driven platform [1][5]. Group 1: Innovation in Healthcare Model - Baize Medical is pioneering the H@H model, which shifts the concept of hospitals from fixed locations to a more dynamic, patient-centered approach that actively engages with patients across different settings [1][6]. - The company has established a standardized operational system and AI-ready intelligent systems, enabling a transition from traditional hospital operations to a technology platform [1][5]. Group 2: Standardization in Medical Services - The lack of standardization in medical services has been a significant barrier to the scalable development of private healthcare. Baize Medical addresses this by transforming experience-based services into a standardized system that can be trained, assessed, and iterated [2]. - The company implements a "source standardization" strategy, embedding standardization into every aspect of healthcare operations, ensuring consistent quality and operational efficiency [2]. Group 3: Continuous Service Loop - The H@H model creates a seamless service loop from admission to home recovery, addressing the issue of patient disengagement post-discharge, thereby enhancing patient compliance, repurchase rates, and long-term loyalty [3]. - For example, in the case of surgical patients, the H@H model allows for continuous monitoring and personalized interventions, significantly improving patient outcomes and resource utilization [3]. Group 4: AI-Ready Data Assets - High-quality, standardized clinical data is crucial for the successful implementation of AI in healthcare. Baize Medical is building a comprehensive, time-sequenced medical data asset that positions it favorably in the industry [4]. - The company has achieved certification for its data assets in lung cancer diagnosis and tumor imaging, establishing a strong foundation for future data capitalization and AI model training [4]. Group 5: Business Model Transformation - Baize Medical's strategic direction focuses on creating a healthcare data asset layer, AI operational infrastructure, and a continuous health management business loop, aiming to transform traditional healthcare profitability models [5]. - This innovative model aligns with market preferences for platform-based healthcare enterprises with technological barriers, potentially capitalizing on the increasing share of commercial health insurance payments [5]. Group 6: Industry Trends and Opportunities - The H@H model is reshaping the rigid boundaries of traditional healthcare, extending services into homes and communities, thus addressing public concerns about access to care and rehabilitation [6]. - As commercial health insurance becomes a significant payment force, Baize Medical's innovative practices are expected to unlock growth potential and provide new pathways for the healthcare industry towards value-driven development [6].

佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月10日南向资金减持32.7万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金减 持的有4天，累计净减持6.42万股。近20个交易日中，获南向资金增持的有11天，累计净增持730.98万 股。截至目前，南向资金持有佰泽医疗（02609.HK）7447.74万股，占公司已发行普通股的5.64%。 ...

| 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2026-02-09 | 7480.44万 | 217.74万 | 3.00% | | 2026-02-06 | 7262.70万 | -36.36万 | -0.50% | | 2026-02-05 | 7299.06万 | -70.50万 | -0.96% | | 2026-02-04 | 7369.56万 | -84.60万 | -1.13% | | 2026-02-03 | 7454.16万 | 304.38万 | 4.26% | 证券之星消息，2月9日南向资金增持217.74万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金 增持的有2天，累计净增持330.66万股。近20个交易日中，获南向资金增持的有11天，累计净增持716.04 万股。截至目前，南向资金持有佰泽医疗（02609.HK）7480.44万股，占公司已发行普通股的5.66%。 佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及 ...